| Symbol | MPLT |
|---|---|
| Name | MAPLIGHT THERAPEUTICS, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 800 CHESAPEAKE DRIVE, REDWOOD CITY, California, 94063, United States |
| Telephone | +1 617 984-6300 |
| Fax | — |
| — | |
| Website | https://maplightrx.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001770069 |
| Description | MapLight Therapeutics is a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system disorders. We were founded by globally recognized leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies available for patients. Our discovery platform holds the potential to fill this void by identifying neural circuits causally linked to disease and targeting those circuits for therapeutic modulation. Additional info from NASDAQ: |
(30% Negative) MAPLIGHT THERAPEUTICS, INC. (MPLT) Reports Q3 2026 Financial Results
Read moreNew Form SCHEDULE 13D/A - MapLight Therapeutics, Inc. <b>Filed:</b> 2026-08-03 <b>AccNo:</b> 0001104659-26-089960 <b>Size:</b> 18 KB
Read moreMPLT Investors Have Opportunity to Join MapLight Therapeutics, Inc. Fraud Investigation with SBS Law
Read more📋 Novo Holdings A/S (Ex-Affiliate) plans to sell 1.6M shares of MAPLIGHT THERAPEUTICS, INC. (at $15.02 each, total $24.0M) Filed: Jul 30, 2026 | ID: 000032
Read moreCatalyst4, Inc. 🟢 acquired 1.2M shares of MapLight Therapeutics, Inc. (MLPT) at $13.00 ($15.3M) Transaction Date: Jul 28, 2026 | Filing ID: 000003
Read moreCox Troy 🟢 acquired 15.6K shares of MapLight Therapeutics, Inc. (MPLT) at $9.52 Transaction Date: Jul 28, 2026 | Filing ID: 000007
Read moreMPLT Investors Have Opportunity to Join MapLight Therapeutics, Inc. Fraud Investigation with SBS Law
Read more(85% Positive) MAPLIGHT THERAPEUTICS, INC. (MPLT) Provides Update on approved for Schizophrenia July 27
Read moreMapLight Therapeutics Announces Positive Topline Results from Phase 2 ZEPHYR Trial of ML-007C-MA in Schizophrenia
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT07459647 | A Long-Term Open-Label Study of ML-007C-MA in Adults With Schizophrenia | Phase2 | Schizophrenia | Recruiting | 2026-03-31 | 2030-02-01 | ClinicalTrials.gov |
| NCT07459660 | An Open-Label Study of ML-007C-MA in Adults With Alzheimer's Disease Psychosis | Phase2 | Psychosis Associated With Alzheimer's Disease | Enrolling_By_Invitation | 2026-03-25 | 2029-03-01 | ClinicalTrials.gov |
| NCT06887192 | A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Al… | Phase2 | Psychosis Associated With Alzheimer's Disease | Recruiting | 2025-08-15 | 2027-12-01 | ClinicalTrials.gov |
| NCT07038876 | A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of In… | Phase2 | Schizophrenia | Completed | 2025-06-27 | 2026-06-11 | ClinicalTrials.gov |
| NCT05889273 | ML-004 Open-Label Extension Study in Adults and Adolescents With Autism Spectru… | Phase2 | Autism Spectrum Disorder | Active_Not_Recruiting | 2023-06-01 | 2027-12-01 | ClinicalTrials.gov |
| NCT05081245 | ML-004 in Adolescents and Adults With Autism Spectrum Disorders (ASD) | Phase2 | Autism Spectrum Disorder | Completed | 2022-09-13 | 2026-04-17 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| ML-007C-MA | Other | Phase PHASE2 | Schizophrenia | RECRUITING | NCT07459647 |
| ML-007C-MA | Other | Phase PHASE2 | Psychosis Associated With Alzheimer's Disease | ENROLLING_BY_INVITATION | NCT07459660 |